Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus
- 27 March 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (8), 3896-3907
- https://doi.org/10.1021/acs.jmedchem.9b01501
Abstract
The critical consequences of human cytomegalovirus (HCMV) infection in the transplant population and in congenitally infected infants, the limited treatment options for HCMV, and the emergence of resistant mutants during existing therapy fueled the search for new anti-HCMV agents. A pp28-luciferase recombinant HCMV was used as a reporter system for high-throughput screening of HCMV inhibitors. Approximately 400,000 compounds from existing libraries were screened. Subsequent validation assays using resynthesized compounds, several virus strains and detailed virology assays resulted in the identification of five structurally unique and selective HCMV inhibitors, active at sub to low µM concentrations. Further characterization revealed that each compound inhibited a specific stage of HCMV replication. Only one compound was also active against herpes simplex virus. Drug combination studies revealed that all five compounds were additive with ganciclovir or letermovir. Future studies will determine the potential for development of these new compounds as anti-HCMV drugs and their use as probes to study virus-host interaction.Keywords
Funding Information
- National Institute on Deafness and Other Communication Disorders (R01DC013550)
- Flight Attendant Medical Research Institute
- National Institutes of Health
- National Institute of General Medical Sciences (R35GM128840)
This publication has 41 references indexed in Scilit:
- Human Cytomegalovirus Inhibition by Cardiac Glycosides: Evidence for Involvement of the hERG GeneAntimicrobial Agents and Chemotherapy, 2012
- A quantitative basis for antiretroviral therapy for HIV-1 infectionNature Medicine, 2012
- Conserved Herpesvirus Kinases Target the DNA Damage Response Pathway and TIP60 Histone Acetyltransferase to Promote Virus ReplicationCell Host & Microbe, 2011
- The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral TerminaseJournal of Virology, 2011
- Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2011
- Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitorsVirology Journal, 2011
- In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246Antimicrobial Agents and Chemotherapy, 2010
- Establishment of a Cell-Based Assay for Screening of Compounds Inhibiting Very Early Events in the Cytomegalovirus Replication Cycle and Characterization of a Compound Identified Using the AssayAntimicrobial Agents and Chemotherapy, 2008
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsNature Medicine, 2008
- Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical librariesProceedings of the National Academy of Sciences of the United States of America, 2006